Izenivetmab Biosimilar - Research Grade

Human

NGF

>1mg/ml

IgG2 - kappa

CHO Cells

Tanezumab Biosimilar - Research Grade (ICH5102), Fasinumab Biosimilar - Research Grade (ICH5152), Fulranumab Biosimilar - Research Grade (ICH5157), Bedinvetmab Biosimilar - Research Grade (ICH5380), Luvagrobart Biosimilar - Research Grade (ICH5665), Ranevetmab Biosimilar - Research Grade (ICH5805)

https://www.imgt.org/mAb-DB/

ICH3002

P01138

Blue ice

ICH5615 is a research-grade, unconjugated recombinant analog of the anti-NGF antibody izenivetmab, built around human nerve growth factor (beta-NGF, UniProt P01138). It is a non-therapeutic biosimilar intended strictly for research use, not for human or veterinary use, and is not the clinical drug itself. Expressed as a human IgG2-kappa immunoglobulin, it reproduces the target specificity of the originator so investigators can study NGF neutralisation, NGF/receptor interactions, and antibody-based blockade in controlled experimental systems. Typical research applications include use as a well-defined positive control or reference antibody, as a neutralising reagent in cell-based and biochemical assays, and as a tool for developing binding, ELISA, and ligand-blocking readouts. The material is supplied unconjugated, allowing downstream labelling or format conversion by the end user. It is offered at low endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg) and in bulk milligram-to-gram quantities suitable for assay development, preclinical in-vitro work, and scale-dependent screening, making it a consistent, characterised alternative to sourcing scarce clinical material for laboratory studies. Nerve growth factor (NGF; beta-NGF, UniProt P01138) is the prototypic neurotrophin, secreted as a mature ~120 aa protein that signals as a non-covalent homodimer. It binds two receptors: the high-affinity receptor tyrosine kinase TrkA (NTRK1), which drives neuronal survival, differentiation, and neurite outgrowth via Ras-MAPK, PI3K-Akt, and PLCgamma pathways, and the low-affinity p75 neurotrophin receptor (NGFR/TNFRSF16), which modulates affinity and can influence apoptotic and survival signalling. NGF is essential for the development and maintenance of sympathetic and sensory neurons. In adults it is a key mediator of nociceptor sensitisation and pain: NGF released during inflammation and tissue injury sensitises peripheral sensory neurons, upregulates pain-related channels and neuropeptides, and contributes to chronic and inflammatory pain states. This nociceptive role underlies the therapeutic interest in NGF-neutralising antibodies.

Beta-NGF, Beta-nerve growth factor, NGFB

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks